OCULAR THERAPEUTIX INC (OCUL) Fundamental Analysis & Valuation

NASDAQ:OCUL • US67576A1007

Current stock price

9.66 USD
+0.34 (+3.65%)
At close:
9.55 USD
-0.11 (-1.14%)
After Hours:

This OCUL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. OCUL Profitability Analysis

1.1 Basic Checks

  • In the past year OCUL has reported negative net income.
  • In the past year OCUL has reported a negative cash flow from operations.
  • OCUL had negative earnings in each of the past 5 years.
  • OCUL had a negative operating cash flow in each of the past 5 years.
OCUL Yearly Net Income VS EBIT VS OCF VS FCFOCUL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • OCUL's Return On Assets of -32.91% is in line compared to the rest of the industry. OCUL outperforms 48.17% of its industry peers.
  • With a Return On Equity value of -40.64%, OCUL perfoms like the industry average, outperforming 57.59% of the companies in the same industry.
Industry RankSector Rank
ROA -32.91%
ROE -40.64%
ROIC N/A
ROA(3y)-35.73%
ROA(5y)-31.6%
ROE(3y)-63.53%
ROE(5y)-79.74%
ROIC(3y)N/A
ROIC(5y)N/A
OCUL Yearly ROA, ROE, ROICOCUL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K 2K

1.3 Margins

  • With an excellent Gross Margin value of 87.35%, OCUL belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
  • OCUL's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for OCUL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.42%
GM growth 5Y-0.16%
OCUL Yearly Profit, Operating, Gross MarginsOCUL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. OCUL Health Analysis

2.1 Basic Checks

  • OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OCUL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, OCUL has more shares outstanding
  • The debt/assets ratio for OCUL has been reduced compared to a year ago.
OCUL Yearly Shares OutstandingOCUL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
OCUL Yearly Total Debt VS Total AssetsOCUL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 5.96 indicates that OCUL is not in any danger for bankruptcy at the moment.
  • OCUL's Altman-Z score of 5.96 is fine compared to the rest of the industry. OCUL outperforms 75.39% of its industry peers.
  • OCUL has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
  • OCUL has a Debt to Equity ratio of 0.11. This is comparable to the rest of the industry: OCUL outperforms 47.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z 5.96
ROIC/WACCN/A
WACC9.65%
OCUL Yearly LT Debt VS Equity VS FCFOCUL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 15.39 indicates that OCUL has no problem at all paying its short term obligations.
  • The Current ratio of OCUL (15.39) is better than 89.01% of its industry peers.
  • A Quick Ratio of 15.32 indicates that OCUL has no problem at all paying its short term obligations.
  • The Quick ratio of OCUL (15.32) is better than 89.01% of its industry peers.
Industry RankSector Rank
Current Ratio 15.39
Quick Ratio 15.32
OCUL Yearly Current Assets VS Current LiabilitesOCUL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. OCUL Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 2.04% over the past year.
  • Looking at the last year, OCUL shows a very negative growth in Revenue. The Revenue has decreased by -18.47% in the last year.
  • The Revenue has been growing by 24.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)2.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y0.3%
Revenue growth 5Y24.45%
Sales Q2Q%-22.44%

3.2 Future

  • Based on estimates for the next years, OCUL will show a very strong growth in Earnings Per Share. The EPS will grow by 26.94% on average per year.
  • Based on estimates for the next years, OCUL will show a very strong growth in Revenue. The Revenue will grow by 76.93% on average per year.
EPS Next Y5.69%
EPS Next 2Y5.94%
EPS Next 3Y5.62%
EPS Next 5Y26.94%
Revenue Next Year0.34%
Revenue Next 2Y40.26%
Revenue Next 3Y76.14%
Revenue Next 5Y76.93%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OCUL Yearly Revenue VS EstimatesOCUL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
OCUL Yearly EPS VS EstimatesOCUL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. OCUL Valuation Analysis

4.1 Price/Earnings Ratio

  • OCUL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year OCUL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCUL Price Earnings VS Forward Price EarningsOCUL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCUL Per share dataOCUL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.94%
EPS Next 3Y5.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OCUL Dividend Analysis

5.1 Amount

  • No dividends for OCUL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OCUL Fundamentals: All Metrics, Ratios and Statistics

OCULAR THERAPEUTIX INC

NASDAQ:OCUL (4/22/2026, 5:39:50 PM)

After market: 9.55 -0.11 (-1.14%)

9.66

+0.34 (+3.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)05-11
Inst Owners89.87%
Inst Owner Change0.12%
Ins Owners2.29%
Ins Owner Change1.35%
Market Cap2.10B
Revenue(TTM)51.95M
Net Income(TTM)-265.94M
Analysts85.56
Price Target26.15 (170.7%)
Short Float %11.95%
Short Ratio3.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.55%
Min EPS beat(2)-1.62%
Max EPS beat(2)12.73%
EPS beat(4)1
Avg EPS beat(4)-5.84%
Min EPS beat(4)-26.63%
Max EPS beat(4)12.73%
EPS beat(8)2
Avg EPS beat(8)-37.37%
EPS beat(12)4
Avg EPS beat(12)-24.95%
EPS beat(16)6
Avg EPS beat(16)-17.93%
Revenue beat(2)0
Avg Revenue beat(2)-10.99%
Min Revenue beat(2)-19.46%
Max Revenue beat(2)-2.51%
Revenue beat(4)0
Avg Revenue beat(4)-15.02%
Min Revenue beat(4)-37.69%
Max Revenue beat(4)-0.44%
Revenue beat(8)1
Avg Revenue beat(8)-9.84%
Revenue beat(12)2
Avg Revenue beat(12)-7.89%
Revenue beat(16)3
Avg Revenue beat(16)-8.44%
PT rev (1m)2.55%
PT rev (3m)5.36%
EPS NQ rev (1m)1.76%
EPS NQ rev (3m)10.35%
EPS NY rev (1m)0.22%
EPS NY rev (3m)7.01%
Revenue NQ rev (1m)1.32%
Revenue NQ rev (3m)-10.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.48
P/FCF N/A
P/OCF N/A
P/B 3.21
P/tB 3.21
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.24
BVpS3.01
TBVpS3.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -32.91%
ROE -40.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.35%
FCFM N/A
ROA(3y)-35.73%
ROA(5y)-31.6%
ROE(3y)-63.53%
ROE(5y)-79.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.42%
GM growth 5Y-0.16%
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 277.82%
Cap/Sales 23.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.39
Quick Ratio 15.32
Altman-Z 5.96
F-Score4
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)171.96%
Cap/Depr(5y)148.27%
Cap/Sales(3y)11.85%
Cap/Sales(5y)9.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y5.69%
EPS Next 2Y5.94%
EPS Next 3Y5.62%
EPS Next 5Y26.94%
Revenue 1Y (TTM)-18.47%
Revenue growth 3Y0.3%
Revenue growth 5Y24.45%
Sales Q2Q%-22.44%
Revenue Next Year0.34%
Revenue Next 2Y40.26%
Revenue Next 3Y76.14%
Revenue Next 5Y76.93%
EBIT growth 1Y-57.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.94%
EBIT Next 3Y29.09%
EBIT Next 5Y32.32%
FCF growth 1Y-59.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.13%
OCF growth 3YN/A
OCF growth 5YN/A

OCULAR THERAPEUTIX INC / OCUL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of OCULAR THERAPEUTIX INC (OCUL) stock?

ChartMill assigns a fundamental rating of 4 / 10 to OCUL.


Can you provide the valuation status for OCULAR THERAPEUTIX INC?

ChartMill assigns a valuation rating of 0 / 10 to OCULAR THERAPEUTIX INC (OCUL). This can be considered as Overvalued.


Can you provide the profitability details for OCULAR THERAPEUTIX INC?

OCULAR THERAPEUTIX INC (OCUL) has a profitability rating of 2 / 10.


What is the financial health of OCULAR THERAPEUTIX INC (OCUL) stock?

The financial health rating of OCULAR THERAPEUTIX INC (OCUL) is 6 / 10.